BUPIVACAINE HYDROCH

Bupivacaine Hydrochloride Injection USP 0.5% in 50 mL vials is being procured under contract SPE2DP-26-T-4347 for delivery to a U.S. military facility in Kwangju, South Korea, with a required delivery date of July 30, 2026. The item is manufactured by Pfizer Inc under NDC 00409-1163-18 and must comply with FDA regulations, requiring pre-award confirmation through EBS referral. The product has a non-extendable 24-month shelf life and must be stored at controlled room temperature between 20°C to 25°C. Packaging and marking must adhere to Medical Marking Standard No. 1, superseding MIL-STD-129, with all units sealed in commercial containers capable of protecting against damage and suitable for low-cost Carrier shipment. Palletization and packaging must meet DLA’s RP001 requirements, and hazardous material shipping protocols under IP025 apply. The contract specifies a fixed quantity of three vials with zero variance allowance, and inspection and acceptance occur at destination. The delivery is FOB destination, with a 20-day lead time and a requirement for government-compliant labeling and documentation. All technical, quality, and packaging specifications are governed by the DLA Master List of Technical and Quality Requirements referenced in RA001, with compliance enforced as of the solicitation issue date.